Priority Pathway News Today

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided an update on regulatory submissions for mRNA-1345, a vaccine for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older.

MRNA-1345 is an investigational RSV vaccine that consists of a single mRNA sequence encoding for a stabilized prefusion F glycoprotein.

Reported €30.2 million in cash and cash equivalents as of March 31, 2023PARIS and CAMBRIDGE, Mass., May 17, 2023 -- NANOBIOTIX , a late-clinical stage biotechnology company pioneering... | May 17, 2023